trending Market Intelligence /marketintelligence/en/news-insights/trending/pyh2-32gmctmrdn5x2jsva2 content esgSubNav
In This List

Compugen appoints 3 directors

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Compugen appoints 3 directors

Compugen Ltd. appointed Gilead Halevy, Kinneret Livnat Savitzky and Sanford Zweifach to its board of directors.

The new directors will replace Dov Hershberg, who recently resigned, and Ruth Arnon and Michal Preminger, who are not standing for re-election.

Halevy is the founding member and general partner of Kedma Capital Partners. Savitzky is the interim CEO and a board member of FutuRX. Zweifach is the founder and the CEO of Nuvelution Pharma Inc.

Israel-based Compugen develops early stage immuno-oncology therapies, aimed at harnessing the immune system to eradicate cancer.